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Decades after the introduction of oral anti-coagulants namely the vitamin K antagonist
(VKA) Warfarin and antiplatelet agents such as Aspirin and Plavix, new classes of direct,
small molecule, novel oral anti-coagulant medications and antiplatelet P2Y12 receptor
inhibitors have recently become available. For the novel oral anticoagulants (NOAC), these
agents can be separated by direct thrombin inhibitors such as Dabigatran and direct
Factor Xa inhibitors such as Rivaroxaban and Apixaban. For next generation antiplatelet
agents such as Ticagrelor and Prasugrel, these new P2Y12 receptor inhibitors form the
cornerstone of therapy for patients with acute coronary syndrome (ACS) or undergoing
percutaneous interventions. These novel oral antithrombotics are revolutionizing the field
of stroke prevention, atrial fibrillation (AF), the management of venous thromboembolism
(VTE) and treatment of ACS. This article reviews the current research developed in
order to identify therapeutic effects and establish net clinical benefits of these new oral
antithrombotics.
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INTRODUCTION
Novel oral anticoagulant (NOAC) and antiplatelet agents are
revolutionizing the field of stroke prevention, atrial fibrillation
(AF), the management of venous thromboembolism (VTE) and
treatment of acute coronary syndrome (ACS). The era of oral
anticoagulation initially began in 1940 with Vitamin K antag-
onists (VKA), at which time it was approved for treatment of
VTE (Soff, 2012). The most common VKA is warfarin and
although widely prescribed for thrombotic disorders, there are a
number of well documented limitations including a narrow ther-
apeutic index, the need for regular monitoring, frequent dose
adjustment and multiple drug and food interactions (Ansell,
2004). Thus, in recent decades, there is development of new
classes of direct, small molecule, NOAC medications. For treat-
ment of patients with non-valvular AF, the US Food and Drug
Administration (FDA) approved the use of dabigatran, rivaroxa-
ban, and apixaban. Additionally, rivaroxaban has been approved
for the treatment of deep vein thrombosis (DVT) and Pulmonary
Embolism (PE), reduction in the risk of recurrent DVT and PE,
and prophylaxis of DVT and PE following both hip and knee
arthroplasty.
There is also a shift seen in the treatment of ACS. Currently,
dual-antiplatelet agents, such as Aspirin and Clopidogrel have
been the cornerstone of therapy for ACS. However, recently
P2Y12 receptor inhibitors, such as Prasugrel and Ticagrelor have
been marketed to help alleviate the burden of bleeding, recur-
rence of ischemic events and response variability seen with use
of Clopidogrel (Franchini, 2009).
With the introduction of these new classes and agents, health
care providers must take into consideration the advantages and
disadvantages of the NOACs and P2Y12 receptor inhibitors com-
pared to the historically used agents. This article will review the
experimental trials under which the NOACs and P2Y12 recep-
tor inhibitors were approved, as well as take into consideration
the pharmacokinetic characteristics and clinical evaluation of
therapeutic effects and net clinical benefit.
EXPERIMENTAL STUDIES-ANTICOAGULANTS
DABIGATRAN
Dabigatran was studied in 4 large randomized controlled tri-
als (RCTs) evaluating its use for VTE prophylaxis in orthopedic
surgery, treatment of acute VTE and in patients with AF.
Re-model
The Prevention of VTE after Total Knee Replacement
(RE-MODEL) study was a phase 3, randomized, double-
blind, multicenter trial that compared the therapeutic effects of
dabigatran 150 and 220mg orally once daily with enoxaparin
40mg subcutaneous (SQ) once daily. 2076 patients were enrolled
and followed for 3 months. The primary efficacy outcome was
a composite of total VTE (venographic or symptomatic) and
mortality during treatment. The primary safety outcome was
the incidence of bleeding events. The primary efficacy outcome
occurred in 37.7% of the enoxaparin group vs. 36.4% of the
dabigatran etexilate 220-mg group and 40.5% of the 150-mg
group. This study showed that the two doses of dabigatran
etexilate were non-inferior to enoxaparin for the prevention of
VTE after total knee replacement (TKR). With regards to the
primary safety outcome, there were no significant differences
between either dose of the dabigatran etexilate and enoxaparin
(Eriksson, 2007a,b).
Re-novate
Dabigatran etexilate vs. Enoxaparin for Prevention of VTE after
Total Hip Replacement (THR): a randomized, double-blind,
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non-inferiority trial (RE-NOVATE) was similar to RE-MODEL
except that it looked at prophylaxis in THR patients. In this
double-blind study, 3, 494 patients were randomized and treated
for a median of 33 days. The therapeutic effects of Dabigatran
150 and 220mg orally once daily was compared to Enoxaparin
40mg SQ once daily. The primary efficacy outcome was a com-
posite of VTE (venographic or symptomatic) and death from all
causes during treatment. The non-inferiority margin for the dif-
ference in rates of thromboembolism was defined as 7.7%. The
primary efficacy outcome was seen in 6.7% of the enoxaparin
group vs. 6.0% of the dabigatran etexilate 220mg group and 8.6%
of the dabigatran etexilate 150mg group. This study showed that
the two doses of dabigatran were non-inferior to enoxaparin for
reducing the risk of total VTE and all-cause mortality after THR.
There was also a similar safety profile among the three groups
as the frequency of bleeding was low and comparable (Eriksson,
2007a,b).
Re-cover and re-cover ii
The RE-COVER study compares the efficacy of dabigatran vs.
warfarin in the treatment of acute VTE. Acute VTE includes
both DVT and PE. It was a randomized, double blind, non-
inferiority trial that all 2564 patients enrolled initially received
parenteral anticoagulation therapy with either unfractionated
intravenous heparin or low-molecular-weight SQ heparin for a
median of 9 days. Patients were then assigned to receive either
dabigatran 150mg twice daily or dose-adjusted warfarin ther-
apy (INR goal, 2.0–3.0). Patients were followed for 6- months
out. The primary efficacy outcome was a 6-month incidence of
recurrent, symptomatic, confirmed VTE and related mortality.
Primary safety outcomes included bleeding events, ACS and other
adverse events. Of those patients who received dabigatran, 2.4%
had recurrent VTE, compared with 2.1% of patients who were
treated with warfarin. In evaluation of the primary safety out-
comes, the rates of death, ACS and abnormal liver function tests
were similar in the two groups (Schulman, 2009).
In the RE-COVER II trial, the objective was to compare the
efficacy and safety of dabigatran vs. warfarin and to essentially
confirm the results of RE-COVER I. All patients initially received
parenteral anticoagulation with warfarin or warfarin-placebo.
Patients were then double-blinded to receive either dabigatran
150mg oral twice daily with a warfarin placebo and sham INR or
warfarin (INR goal 2.0–3.0) with a dabigatran placebo. The pri-
mary efficacy outcome, similar to RE-COVER I was a 6-month
incidence of recurrent, symptomatic, confirmed VTE, and related
mortality. At 6 months, of the 1279 patients randomized to dabi-
gatran, 2.4% had recurrent VTE as compared to 2.2% of patients
that received warfarin (HR 1.08; P < 0.0001). There were sim-
ilar safety outcomes between the two groups. This study thus
confirmed results of the initial RE-COVER trial reporting that
dabigatran is as effective as warfarin for treatment of acute VTE
with lower risk of bleeding (Schulman, 2011).
Re-ly
Warfarin reduces the risk of stroke in patients with AF but is
difficult to use because it increases the risk of hemorrhage and
requires laboratory monitoring. The Randomized Evaluation of
Long-Term Anticoagulation Therapy (RE-LY) study was a non-
inferiority trial that compared fixed doses of dabigatran with
dose- adjusted warfarin. There were 18, 113 patients enrolled
with non-valvular AF who had an indication for anticoagula-
tion therapy. Indications for anticoagulation therapy included a
CHADS2 score consistent with an intermediate to high risk of
stroke. Patients were double-blinded and randomized to receive
dabigatran 110mg twice daily, dabigatran 150mg twice daily or
open-label use of dose-adjusted warfarin (INR goal, 2.0–3.0). The
primary endpoint included stroke or systemic embolism (SSE).
The primary safety outcome included major hemorrhage. With a
median follow up of 2 years, they found that both doses of dabiga-
tran were non-inferior to warfarin. The incidence SSE was 1.69%
per year in patients managed with warfarin, compared to the
1.53% per year in patients managed with dabigatran 110mg twice
daily and 1.11% per year in patients managed with dabigatran
150mg twice daily. The 150mg dose of dabigatran was also supe-
rior to warfarin [relative risk, 0.66; 95% confidence interval (CI),
0.53 to 0.82; p < 0.001]. The primary safety outcome of major
bleeding revealed similar rates among all 3 drugs; 3.36% per year
in the warfarin group compared with 2.71% per year in the dabi-
gatran 110mg group and 3.11% per year in the dabigatran 150mg
group.
The overwhelming complication of warfarin therapy is
intracranial hemorrhage, especially hemorrhagic stroke. When
compared with aspirin, warfarin doubles the risk of intracranial
hemorrhage (Lassen, 2010a,b). The RE-LY study found that the
rate of this complication was less than one-third the rate of war-
farin when compared with either dose of dabigatran. This was
also reported without a reduction in the efficacy against ischemic
stroke (Connolly, 2009).
RIVAROXABAN
Record trials
Prophylaxis for VTE after total knee arthroplasty is recommended
for at least 10 days (Caprini, 2006). In the Rivaroxaban vs.
Enoxaparin for Thrombophylaxis After Total Knee Arthroplasty
(RECORD 4) study, 3148 patients were randomized in a double-
blind and double-dummy fashion to receive either rivaroxaban
10mg once daily or enoxaparin 30mg every 12 h. Patients had
mandatory bilateral venography and were followed for up to 35
days. The primary efficacy outcome was composite of any DVT,
non-fatal PE or death from any cause up to day 17 after surgery.
The primary safety outcome was major bleeding. Rivaroxaban
10mg once daily for 10-14 days was found to be superior to
enoxaparin 30mg every 12 h for the prevention of VTE after total
knee arthroplasty (6.7% for rivaroxaban vs. 9.3% for enoxaparin).
In the modified intention-to-treat population, the primary effi-
cacy outcome occurred in 6.9% of patients in the rivaroxaban
arm and 10.1% of patients in the enoxaparin arm. The pri-
mary safety outcome was similar in both arms of the study
(Turpie, 2009).
The results of the RECORD-4 trial were consistent with sim-
ilarly designed trials, RECORD-1, RECORD-2, and RECORD-3.
These trials compared similar doses of rivaroxaban with differ-
ent doses of enoxaparin in the treatment of post- arthroplasty
patients.
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In the RECORD-1 study, rivaroxaban 10mg daily proved to
be superior to enoxaparin 40mg SQ doses the evening prior
to surgery. The primary efficacy outcome of composite VTE
and all-cause mortality for patients undergoing elective total hip
arthroplasty occurred in 1.1% in the rivaroxaban group compared
with 3.7% in the enoxaparin group (ARR, 2.6%; 95% CI, 1.5–3.7;
P < 0.001). Both treatment agents were given on average for 33
days (Eriksson, 2008).
In the RECORD-2 trial, the treatment duration of rivaroxa-
ban 10mg daily was extended for 31–39 days and compared to
enoxaparin 40mg, 10–14 days SQ once daily dosing in patients
undergoing elective total hip arthroplasty. In the primary out-
come of composite VTE and all cause mortality, treatment with
rivaroxaban showed superior efficacy compared to enoxaparin
(2.0% vs. 9.3%; ARR, 7.3%; 95% CI, 5.2–9.4; P < 0.001). There
were similar results with regards to bleeding events between the
two treatments (Kakkar, 2008).
The RECORD-3 study was similar in design to RECORD-1,
except that the treatment period was shorter in length, specifi-
cally 10 to 14 days of therapy. The primary efficacy outcome of
composite of VTE and all-cause mortality occurred in 9.6% in the
rivaroxaban group compared to 18.9% in the enoxaparin group
(ARR, 9.2%; 95%CI, 5.9–12.4; P < 0.001). There were similar
bleeding incidences in both groups (Lassen, 2008).
Einstein-dvt
The Oral Rivaroxaban for Symptomatic VTE (EINSTEIN-DVT)
was an open-label, event-driven, non-inferiority trial of 3449
patients that were randomized to either rivaroxaban monother-
apy 15mg twice daily for 3 weeks, followed by 20mg once daily)
vs. conventional anticoagulation enoxaparin 1mg/kg, followed by
VKA therapy (either warfarin or acenocoumarol). Patients were
followed for 3, 6, or 12 months. The primary efficacy outcome
was recurrent VTE. Rivaroxaban treated subjects had a 2.1% event
rate compared with a 3.0% event rate in the enoxaparin-VKA
arm. Thus, rivaroxaban had non-inferior efficacy. The principal
safety outcome of major bleeding or clinically relevant non-
major bleeding occurred in 8.1% of the patients in each group
(Bauersachs, 2010).
Einstein-pe
Similar to the EINSTEIN-DVT study, the Oral Rivaroxaban
for Treatment of Symptomatic Pulmonary Embolism
(EINSTEIN-PE) compared rivaroxaban therapy (15mg twice
daily for 3 weeks, followed by 20mg once daily) with standard
therapy of enoxaparin followed by a dose-adjusted VKA for 3, 6,
and 12 months. The primary efficacy outcome was symptomatic
recurrent VTE, which resulted in 2.1% of patients on rivaroxaban
therapy, compared with 1.8% of patients on standard VKA
therapy. Thus, rivaroxaban proved to be non-inferior in terms
of efficacy. The principal safety outcome was major bleeding
or clinically relevant non-major bleeding and occurred in the
rivaroxaban group at 10.3% vs. 11.4% of patients in the standard
therapy arm (Buller, 2012).
Rocket-af
In the Rivaroxaban vs. Warfarin in Non-valvular Atrial
Fibrillation (ROCKET-AF) trial, 14,264 patients with
non-valvular AF were randomly assigned to receive either
rivaroxaban at a daily dose of 20mg or dose-adjusted warfarin.
The per protocol, as treated primary analysis was designed to
determine whether rivaroxaban was non-inferior to warfarin
for the primary endpoint of SSE. The initial analysis revealed
that 1.7% per year of patients in the rivaroxaban group had
SSE vs. 2.2% per year of patients in the warfarin group. There
were similar numbers with regards to the intention to treat
analysis (rivaroxaban group, 2.1% per year vs. the warfarin
group, 2.4% per year). There were significant results with regards
to the primary safety end point with significant reductions in
intracranial hemorrhage (0.5% vs. 0.7%; P = 0.02) and fatal
bleeding (0.2% vs. 0.5%; P = 0.003) in the rivaroxaban group
compared to the warfarin group (Patel, 2011).
APIXABAN
Advance-1, -2, and -3
With the above trials depicting that neither dabigatran or rivarox-
aban were superior to low-molecular weight heparins or VKA,
Apixaban, a potent, reversible, direct Factor Xa inhibitor wasmar-
keted for thromboprophylaxis after TKR or THR. In the Apixaban
or Enoxaparin for Thromboprophylaxis after Knee Replacement
(ADVANCE-1) trial, apixaban 2.5mg twice daily was compared
with enoxaparin 30mg twice daily for an average of 12 days
after TKR. The primary efficacy outcome was a composite of
asymptomatic and symptomatic DVT, non-fatal PE and death
from any cause. This study found that apixaban did not achieve
non-inferiority when compared to enoxaparin (Lassen, 2009).
The ADVANCE-2 trial compared apixaban 2.5mg twice daily
against a lower dose enoxaparin at 40mg once daily. The pri-
mary efficacy outcome remained the same and found apixaban
to be superior to enoxaparin [15% of apixaban vs. 25% of enoxa-
parin (relative risk 0.62 [95% CI 0.51–0.74]; p < 0.0001)]. There
was no difference in frequency of major or clinically relevant
non-major bleeding between the two groups (Lassen, 2010a,b).
The third trial, ADVANCE-3 evaluated apixaban 2.5mg twice
daily with enoxaparin 40mg once daily in. Among the 1949
patients enrolled, the primary efficacy outcome occurred in 1.4%
of the apixaban group, compared to 3.9% of the enoxaparin
group. This study, analogous to ADVANCE-2 depicted that in
patients undergoing hip replacement, thromboprophylaxis with
apixaban as compared with enoxaparin was associated with lower
rates of VTE without increased bleeding (Lassen, 2010a,b).
Aristotle
In the randomized, double-blind, placebo- controlled Apixaban
vs. Warfarin in Patients with AF (ARISTOTLE) trial, 18,201
patients with AF and at least one additional risk factor for stroke
were randomized to receive either apixaban 5mg twice daily or
dose- adjusted warfarin (with an INR goal of 2.0–3.0). The pri-
mary outcome was ischemic or hemorrhagic SSE. After a median
follow up of 1.8 years, the rate of ischemic or hemorrhagic SSE
was 1.27% per year in the apixaban group, as compared with
1.60% per year in the warfarin group. Thus, apixaban proved to
be non-inferior to warfarin with regards to treatment. However,
apixaban proved to be superior for stroke prevention (P = 0.01).
In the primary safety outcome of major bleeding, apixaban had a
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significantly lower rate at 2.13% per year vs. 3.09% per year in the
warfarin group (HR, 0.69; 95% CI, 0.60–0.80; p < 0.001). There
were also significant results in the rate of intracranial hemorrhage
with 0.33% per year in the apixaban group and 0.80% per year
in the warfarin group (HR, 0.42; 95% CI, 0.30–0.58; P < 0.001)
(Granger, 2011).
Averroes
VKA therapy has unfavorable side effects, particularly bleeding
or inconvenience. This precludes some patients from receiving
VKA for stroke prevention. In such cases, patients are subjected
to aspirin or other antiplatelet therapy, which has been proven
to have much lower risk reduction when compared to warfarin
(Hart, 2007). The Apixaban Vs. Acetylsalicylic Acid to Prevent
Strokes in AF Patients who have failed or are unsuitable for VKA
Treatment (AVERROES) trial studied the efficacy of apixaban to
prevent stroke in AF patients who were deemed unsuitable can-
didates for VKA therapy. 5,599 patients were randomly assigned
to receive apixaban 5mg twice daily or aspirin (81 to 324mg per
day) based upon the local investigator. Although the primary out-
come was SSE, there was clear benefit in favor of apixaban and
thus the study was terminated. The initial results from 1.1 years
of follow-up showed that the primary outcome of SSE occurred
in 51 patients (1.6% per year) vs. 113 patients (3.7% per year) in
the aspirin group. There were no significant differences in risk of
bleeding between the two groups (Connolly, 2011).
Amplify-vte
Recently published, is the Oral Apixaban for the Treatment of
Acute VTE trial, which studied administering apixaban at fixed
doses to simplify treatment of acute VTE. In this randomized,
double blind study, apixaban 10mg twice daily for 7 days, fol-
lowed by apixaban 5mg twice daily for 6 months was compared
to conventional therapy of enoxaparin and warfarin. ∼5,395
patients with acute VTE were followed with the primary efficacy
outcome being recurrent, symptomatic VTE and related mortal-
ity. The primary efficacy outcome occurred in 2.3% of patients in
the apixaban group as compared with 2.7% in the enoxaparin and
warfarin group (RR, 0.84%; 95% CI, 0.60–1.18; P < 0.001). The
primary safety outcome of major bleeding alone occurred in 0.6%
of patients who received apixaban compared to 1.8% of patients
who received conventional therapy (RR, 0.31; 95% CI, 0.17–0.55;
P < 0.001 for superiority). Thus, a fixed dose of apixaban is non-
inferior to conventional therapy for treatment of acute VTE with
a significantly decreased bleeding risk (Agnelli, 2013).
EXPERIMENTAL STUDIES-ANTIPLATELETS
TICAGRELOR
Plato
The Ticagrelor vs. Clopidogrel in Patients with ACS (PLATO) trial
was a multicenter, double-blind, randomized trial in which tica-
grelor (180mg loading dose, 90mg twice daily thereafter) was
compared to clopidogrel (300 to 600mg loading dose, 75mg daily
thereafter) for the prevention of cardiovascular events. 18, 624
patients that were admitted to the hospital with an ACS, with or
without ST-segment elevation were enrolled and followed for 12
months. The primary end point was a composite of death from
vascular causes, myocardial infarction (MI) or stroke. The pri-
mary outcome occurred in 9.8% of patients receiving ticagrelor
as compared with 11.7% of patients receiving clopidogrel (haz-
ard ratio, 0.84; 95% CI, 0.77–0.92; P < 0.001). There were also
significant differences in the rates ofMI alone and death from vas-
cular causes but not stroke alone. The rate of death from any cause
was also reduced in the ticagrelor group vs. the clopidogrel group
(4.5% vs. 5.9%; P < 0.001). Thus, treatment with ticagrelor as
compared with clopidogrel significantly reduced the rate of death
from vascular causes, MI or stroke without an increase in the rate
of overall major bleeding in patients with ACS with or without
ST-segment elevation. In the analysis, the superiority of ticagrelor
vs. clopidogrel was not seen in the western population (Wallentin,
2009).
PRASUGREL
Trilogy-acs
The Prasugrel vs. Clopidogrel for ACS without Revascularization
(TRILOGY) study was a double-blind, randomized trial to deter-
mine the effect of intensified platelet inhibition for patients
with unstable angina (USA) or MI without ST-segment eleva-
tion without surgical intervention. The primary analysis involved
7243 patients under the age of 75, already on aspirin who
were randomized to receive prasugrel (10mg daily) vs. clopi-
dogrel (75mg daily). A secondary analysis for patients over
75 years old involved 2083 patients who were randomized to
receive prasugrel 5mg vs. clopidogrel 75 mg. The primary end
points included death from cardiovascular causes, MI or stroke.
At a median follow-up of 17 months, the primary outcome
occurred in 13.9% of patients in the prasugrel group and 16.0%
of patients in the clopidogrel group (P = 0.21). There was
no significant difference in the frequency of non-hemorrhagic
serious adverse events, except for a higher frequency of heart
failure in the clopidogrel group. Thus, there is no significant
difference between prasugrel and clopidogrel among patients
with unstable angina or MI without ST-segment elevation (Roe,
2012).
PHARMACOLOGY
VITAMIN K ANTAGONISTS-WARFARIN
Warfarin is a VKA that achieves its anticoagulant effects by
inhibiting the synthesis of factors II, VII, IX, and X. All pathways
of the coagulation cascade are affected with resultant prolonga-
tion of the prothrombin time (PT), the international normal-
ized ratio (INR) and the partial thromboplastin time (PTT).
Specifically, factor II and X prolongs the PT/INR and PTT, as it
is a part of the common pathway. Factor VII, part of the extrin-
sic pathway, prolongs the PT/INR. Finally, factor IX, part of the
intrinsic pathway, prolongs the PTT (Ageno, 2012). Warfarin is
rapidly absorbed and has a half-life of 36 to 42 h. It is both
the pharmacokinetics of warfarin, as well as the half-life of the
factors involved in the coagulation cascade that contribute to
warfarin’s delayed therapeutic effect and the necessity of bridg-
ing therapy. The liver, specifically the cytochrome p450 enzymes,
metabolizes warfarin. Thus, other medications, herbal remedies
and diet influence its pharmacokinetics. This in turn necessitates
monitoring the INR (Dittus, 2013).
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DIRECT THROMBIN INHIBITORS-DABIGATRAN
Dabigatran etexilate is a direct thrombin inhibitor that is the
prodrug of the active compound dabigatran. It binds reversibly
to thrombin with high affinity and specificity (Hauel, 2002). It
has a rapid onset of action and inhibits both free and fibrin-
bound thrombin. This unique characteristic is what differentiates
it from heparin, which only inhibits free thrombin. It has a half-
life of ∼12 to 14 h, pending on renal function as it is excreted via
the kidneys. The anticoagulant effect of dabigatran is predictable
and thus does not require monitoring. This specific property dif-
ferentiates it from warfarin and thus makes it user-friendly for
patients. As it targets the common pathway, dabigatran affects
both the PTT and the thrombin time. One of the disadvantages
of dabigatran is the lack of a reversible agent or antidote (Nisio,
2005).
DIRECT FACTOR XA INHIBITORS-RIVAROXABAN; APIXABAN
Rivaroxaban is a direct factor Xa inhibitor with high selectivity.
It is inhibits thrombin generation by inhibiting factor Xa formu-
lated via the intrinsic and extrinsic coagulation pathways. Thus, it
prolongs both the PT and activated partial thromboplastin time
(aPTT). However, unlike warfarin, there is no use in monitor-
ing the pharmacodynamics effects of rivaroxaban because these
parameters vary significantly depending on the clotting assays
(Perzborn, 2010). The bioavailability of a 10mg dose of rivarox-
aban is extremely high (80–100%). It is rapidly absorbed and has
a half-life of 7–11 h for young patients without any significant
accumulation with repeat dosing. Rivaroxaban has a dual mode
of elimination with two-thirds of the drug undergoing metab-
olization via the liver and the other one-third remaining as an
unchanged drug that is excreted in the urine (Kreutz, 2012).
Apixaban also directly and reversibly binds and inhibits fac-
tor Xa in both its free and bound forms. It has about 66%
bioavailability and a half-life of 9 to 14 h. It is metabolized by
the cytochrome p450 system in the liver and is excreted by renal
and fecal systems. Like rivaroxaban, there is no use in monitoring
apixaban because it affects both the PT/INR and aPTT with high
variability (Prom, 2011).
P2Y12 RECEPTOR INHIBITORS-PRASUGREL, TICAGRELOR
Prasugrel is a third-generation thienopyridine, which irreversibly
inhibits the P2Y12 platelet receptor. It is administered orally with
a loading dose of 60mg and maintenance dose of 10mg once
daily. The time to peak-onset of action is 2 h with a half-life of
3.7 h. It is metabolized into active and inactive metabolites with
the active metabolites having an elimination half-life of about 7 h.
Prasugrel is contraindicated in patients with a history of stroke or
TIA and there is a warning of increased bleeding risk in patients
>75 years and<60 kilograms (Damman, 2012).
Ticagrelor has started revolutionizing the field of ACS, because
unlike clopidogrel and prasugrel, ticagrelor is a reversible oral
P2Y12 receptor inhibitor that acts at a different site from the ADP
binding site. It is also administered orally without any metabolic
activation necessary. The loading dose is 180mg with a main-
tenance dose of 90mg three times a day. Time to peak onset is
2 h with a half- life of 6–13 h. Ticagrelor is contraindicated in
patients with severe hepatic impairment and some limitations
include dose-related dyspnea, multiple daily dosing and bleeding
(Shivani, 2013).
PATIENT CONSIDERATIONS
MONITORING AND ANTICOAGULANT EFFECTS
As with any of the above antithrombotics, bleeding risk is always a
concern for health care providers. Bleeding risk is associated with
inadequate time in the therapeutic range for patients, especially
those patients on VKAs, i.e., warfarin, that require INR monitor-
ing. Adequate time in therapeutic range for patients is estimated
to be ∼65% in patients who are followed in specialty coagulation
clinics and even lower for those patients followed in a primary
care setting (Baker, 2009). Althoughmonitoring does place a bur-
den on both the physician and patient, frequent physician visits
can provide ongoing patient education.
With the new antithrombotic agents available, routine mon-
itoring in a clinical setting is not necessary. Dabigatran and the
factor Xa inhibitors do not require routine monitoring. However,
with any of the agents, patients must be educated on the antico-
agulant effects. As the half-life of warfarin is 36 to 42 h, patients
are able to miss one dose and still remain fully anticoagulated.
However, with dabigatran, as the half-life is 12–14 h, even miss-
ing one dose can lead to a significant loss of anticoagulant effects.
The half-lives of the factor Xa inhibitors are even shorter than
dabigatran and thus closely adhering to the dosing regimen and
compliance is important to achieve full anticoagulant effects
(Blommel, 2011; Prom, 2011; Ageno, 2012; Kreutz, 2012; Shivani,
2013).
RENAL IMPAIRMENT
With renal disease becoming more prevalent, it is important to
understand the role of anticoagulants and antithrombotics in
this specific group of patients. Although VKAs are considered
difficult to use because of monitoring, necessary dose adjust-
ments and multiple drug and food interactions, it does have
its advantages. One of these advantages include drug clearance
independent of renal function. Unlike warfarin, dabigatran and
rivaroxaban have >80% and >60% renal excretion respectively.
In certain of the above stated experimental studies, including
RE-LY and ROCKET-AF, patients with a Creatinine Clearance
(CrCl) <30mL/min were excluded as to the known increase risk
of bleed (Hauel, 2002; Perzborn, 2010; Kreutz, 2012).
In the case of antiplatelet agents, there are no dose adjustments
necessary and only a caution of using prasugrel with moder-
ate renal impairment (CrCl 30–50mL/min). Similarly, there are
no renal dose adjustments recommended in ticagrelor’s product
characteristics. There needs to be further research regarding the
safety of P2Y12 antagonists in the context of renal impairment.
REVERSAL
Reversal of any anticoagulant or antiplatelet agent is important.
This aspect is important in patients requiring urgent invasive pro-
cedures, bleeding patients or elevated laboratory measurements.
One of the benefits of warfarin is that it can be reversed with
known strategies. If a patient is stable enough, the first step usu-
ally involves holding a dose of warfarin. If reversal is needed
urgently, dosing Vitamin K can help initiate hepatic production
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of the vitamin K-dependent clotting factors. This effect can be
seen within 12 to 24 h when checking repeat INR levels. In
the case where even more rapid reversal is needed, fresh frozen
plasma (FFP) or prothrombin complex concentrate (PCC) can be
administered (Ageno, 2012).
There is no available antidote to reverse dabigatran. Thus,
most strategies involve discontinuing the agent in hopes that 50%
of the drug will be cleared in 12 to 18 h. The other strategies
include repletion of coagulation factors or hemodialysis, although
hemodialysis is not feasible in emergent life-threatening bleeding
situations (Blommel, 2011; Ageno, 2012). Rivaroxaban and apix-
aban also do not have antidotes available if necessary. Although
rivaroxaban has 65% renal excretion, the very high plasma pro-
tein binding prevents it from being dialyzable. Apixaban has
multiple sites of elimination including the liver, kidney and
gastrointestinal tract. There are early reports of antidotes for
the NOACs undergoing early phase clinical studies that show
promise in the ability to reverse their anticoagulant effects (Dager,
2013).
The importance of continuing anti-platelet agents in ACS
and percutaneous coronary intervention (PCI) is well-known
and has been well studied. However, there has been little in
research of reversal of these antiplatelet agents. Currently, strate-
gies to reestablish platelet aggregation are used but without any
established guidelines or recommendations.
CONCLUSIONS
The emergence of the small-molecule, target-specific NOACs has
the potential to revolutionize the acute and long-term man-
agement of patients with venous and arterial thromboembolic
disorders. They are at least equally effective and likely safer than
conventional anticoagulants such as heparin and warfarin, and
all 3 agents lead to a clinically important reduction in intracra-
nial hemorrhagic risk. They provide simplicity of dosing without
the need for routine monitoring and predictable pharmacoki-
netic and pharmacodynamics effects of their anticoagulant activ-
ity with little drug and food interactions. Lastly, apixaban and
rivaroxaban provide a monotherapy approach with an oral agent
for the acute treatment of patients with venous thromboembolic
disease. Comparisons between the new target specific oral anti-
coagulants are not possible due to lack of head to head trials. In
the United States, all three drugs have already been FDA approved
for stroke prevention in non-valvular AF patients. With regards to
treatment of VTE, rivaroxaban is the only FDA approved drug in
the United States.
The second-generation P2Y12 inhibitors prasugrel and tica-
grelor have the potential to further refine net clinical benefit over
existing agents such as clopidogrel for themanagement of patients
with ACS. For treatment of ACS with or without ST-segment ele-
vation, ticagrelor has been proven to significantly reduce the rate
of ischemic events.
These novel OACs and antiplatelet agents are coveted because
of their desirable and predictable pharmacokinetics and phar-
macodynamics profiles. Although much is known about their
dosing, half-life, and metabolism, further research is necessary
to see their effects in special patient populations such as the
elderly, patients with renal insufficiency and patients with high
bleed risk or on multiple antithrombotic agents. Patient educa-
tion as to their effects and need for dose adherence is important.
Further research regarding urgent or emergent reversal, patient
adherence and monitoring in special clinical situations or patient
populations will be necessary.
REFERENCES
Ageno, W. (2012). Oral anticoagulant
therapy: antithrombotic therapy
and prevention of thrombosis, 9th
ed: American College of Chest
Physicians evidence-based clinical
practice guidelines. Chest 141,
e44S–e88S. doi: 10.1378/chest.11-
2292
Agnelli, G. (2013). Oral apixa-
ban for the treatment of acute
venous thromboembolism. N.
Engl. J. Med. 369, 799–808. doi:
10.1056/NEJMoa1302507
Ansell, J. (2004). The pharmacology
and management of the vitamin
K antagonists: the Seventh AACP
Conference on Antithrombotic and
Thrombolytic Therapy. Chest 126,
204S–233S. doi: 10.1378/chest.126.3
_suppl.204S
Baker, W. I. (2009). Meta-analysis to
asses the quality of warfarin con-
trol in atrial fibrillation patients in
the United States. J. Manag. Care
Pharm. 15, 244–252.
Bauersachs, R. (2010). Oral rivarox-
aban for symptomatic venous
thromboembolism. N. Engl.
J. Med. 363, 2499–2510. doi:
10.1056/NEJMoa1007903
Blommel, M. (2011). Dabigatran
etexilate: a novel oral direct
thrombin inhibitor. Am. J. Health
Syst. Pharm. 68, 1506–1519. doi:
10.2146/ajhp100348
Buller, H. R. (2012). Oral rivaroxa-
ban for the treatment of symp-
tomatic pulmonary embolism. N.
Engl. J. Med. 366, 1287–1297. doi:
10.1056/NEJMoa1113572
Caprini, J. A. (2006). Compliance with
antithrombotic guidelines. Manag.
Care 15, 49–66.
Connolly, S. J. (2009). Dabigatran
versus warfarin in patients
with atrial fibrillation. N. Engl.
J. Med. 361, 1139–1151. doi:
10.1056/NEJMoa0905561
Connolly, S. J. (2011). Apixaban in
patients with atrial fibrillation. N.
Engl. J. Med. 364, 806–817. doi:
10.1056/NEJMoa1007432
Dager, W. E. (2013) Developing
a management plan for oral
anticoagulant reversal. Am. J.
Health-System Pharm. 70, 521–531.
doi: 10.2146/ajhp130042
Damman, P. (2012). P2Y12 platelet
inhibition in clinical practice.
J. Thromb. Thrombolysis 33,
143–155. doi: 10.1007/s11239-011-
0667-5
Dittus, C. (2013). The evolution
of oral anticoagulant therapy.
Prim. Care 40, 109–134. doi:
10.1016/j.pop.2012.11.011
Eriksson, B. I. (2007a). Dabigatran
etexilate versus enoxaparin for
prevention of venous thromboem-
bolism after total hip replacement:
a randomised, double-blind,
non-inferiority trial. Lancet 370,
949–956. doi: 10.1016/S0140-6736
(07)61445-7
Eriksson, B. I. (2007b). Oral dabigatran
etexilate vs. subcutaneous enoxa-
parin for the prevention of venous
thromboembolism after total knee
replacement: the RE-MODEL ran-
domized trial. J. Thromb. Haemost.
5, 2178–2185. doi: 10.1111/j.1538-
7836.2007.02748.x
Eriksson, B. I. (2008). Rivaroxaban
versus enoxaparin for
thromboprophylaxis after
hip arthroplasty. N. Engl. J.
Med. 358, 2765–2775. doi:
10.1056/NEJMoa0800374
Franchini, M. (2009). New antiplatelet
agents: why they are needed. Eur.
J. Intern. Med. 20, 733–738. doi:
10.1016/j.ejim.2009.09.005
Granger, C. B. (2011). Apixaban
versus warfarin in patients
with atrial fibrillation. N. Engl.
J. Med. 365, 981–992. doi:
10.1056/NEJMoa1107039
Hart, R. G. (2007). Meta-analysis:
antithrombotic therapy to pre-
vent stroke in patients who have
nonvalvular atrial fibrillation.
Ann. Intern. Med. 146, 857–867.
doi: 10.7326/0003-4819-146-12-
200706190-00007
Hauel, N. H. (2002). Structure-
based design of novel potent
nonpeptide thrombin inhibitors.
J. Med. Chem. 45, 1757–1766. doi:
10.1021/jm0109513
Kakkar, A. K. (2008). Extended dura-
tion rivaroxaban versus short-term
enoxaparin for the prevention of
venous thromboembolism after
total hip arthroplasty: a double-
blind, randomized controlled
Frontiers in Pharmacology | Cardiovascular and Smooth Muscle Pharmacology October 2013 | Volume 4 | Article 133 | 6
Pudusseri et al. Novel antithrombotics in the management of thromboembolic disease
trial. Lancet 372, 31–39. doi:
10.1016/S0140-6736(08)60880-6
Kreutz, R. (2012). Pharmacodynamic
and pharmacokinetic basics
of rivaroxaban. Fundam. Clin.
Pharmacol. 26, 27–32. doi:
10.1111/j.1472-8206.2011.00981.x
Lassen, M. R. (2008). Rivaroxaban
versus enoxaparin for throm-
boprophylaxis after total knee
arthroplasty. N. Engl. J. Med. 358,
2776–2786. doi: 10.1056/
NEJMoa076016
Lassen, M. R. (2009). Apixaban or
enoxaparin for thromboprophy-
laxis after knee replacement. N.
Engl. J. Med. 361, 594–604. doi:
10.1056/NEJMoa0810773
Lassen, M. R. (2010a). Apixaban ver-
sus enoxaparin for thrombopro-
phylaxis after total knee replace-
ment (ADVANCE-2): a random-
ized double-blind trial. Lancet 375,
807–815. doi: 10.1016/S0140-6736
(09)62125-5
Lassen, M. R. (2010b). Apixaban
versus enoxaparin for throm-
boprophylaxis after hip
replacement. N. Engl. J. Med. 363,
2487–2498. doi: 10.1056/NEJMo
a1006885
Nisio, M. (2005). Direct throm-
bin inhibitors. N. Engl. J. Med.
353, 1028–1040. doi: 10.1056/
NEJMra044440
Patel, M. R. (2011). Rivaroxaban
versus warfarin in patients with
nonvalvular atrial fibrillation. N.
Engl. J. Med. 365, 883–891. doi:
10.1056/NEJMoa1009638
Perzborn, E. (2010). Rivaroxaban:
a new oral factor Xa inhibitor.
Arterioscler. Thromb. Vasc. Biol. 30,
376–381. doi: 10.1161/ATVBAHA.
110.202978
Prom, R. (2011). The role of apix-
aban for venous and arterial
thromboembolic disease. Ann.
Pharmacother. 45, 1262–1283. doi:
10.1345/aph.1Q119
Roe, M. (2012). Prasugrel versus clopi-
dogrel for acute coronary syn-
dromes without revascularization.
N. Engl. J. Med. 367, 1297–1309. doi:
10.1056/NEJMoa1205512
Schulman, S. (2009). Dabigatran ver-
sus warfarin in the treatment of
acute venous thromboembolism. N.
Engl. J. Med. 361, 2342–2352. doi:
10.1056/NEJMoa0906598
Schulman, S. (2011). “A randomized
trial of dabigatran versus warfarin
in the treatment of acute venous
thromboembolism (RE-COVER
II),” American Society of Hematology
2011 Annual Meeting (San Diego,
CA).
Shivani, J. (2013). Ticagrelor: an
emerging oral antiplatelet agent.
J. Pharmacol. Pharmacother. 4,
78–80. doi: 10.4103/0976-500X.
107698
Soff, G. A. (2012). A new genera-
tion of oral direct anticoagulants.
Arterioscler. Thromb. Vasc. Biol. 32,
569–574. doi: 10.1161/ATVBAHA.
111.242834
Turpie, A. G. (2009). Rivaroxaban
versus enoxaparin for thrombo-
phylaxis after total knee arthro-
plasty (RECORD 4): randomised
trial. Lancet 373, 1673–1680. doi:
10.1016/S0140-6736(09)60734-0
Wallentin, L. (2009). Ticagrelor ver-
sus clopidogrel in patients with
acute coronary syndromes. N.
Engl. J. Med. 361, 1045–1057. doi:
10.1056/NEJMoa0904327
Conflict of Interest Statement: The
authors declare that the research
was conducted in the absence of any
commercial or financial relationships
that could be construed as a potential
conflict of interest.
Received: 26 July 2013; accepted: 04
October 2013; published online: 21
October 2013.
Citation: Pudusseri A, Shameem R and
Spyropoulos AC (2013) A new paradigm
shift in antithrombotic therapy. Front.
Pharmacol. 4:133. doi: 10.3389/fphar.
2013.00133
This article was submitted to
Cardiovascular and Smooth Muscle
Pharmacology, a section of the journal
Frontiers in Pharmacology.
Copyright © 2013 Pudusseri, Shameem
and Spyropoulos. This is an open-access
article distributed under the terms of
the Creative Commons Attribution
License (CC BY). The use, distribu-
tion or reproduction in other forums
is permitted, provided the original
author(s) or licensor are credited and
that the original publication in this
journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is permit-
ted which does not comply with these
terms.
www.frontiersin.org October 2013 | Volume 4 | Article 133 | 7
